Effects of coadministered antiepileptic drugs on free fractions of phenobarbital and valproic acid in epileptic children. 1986

S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo

UI MeSH Term Description Entries
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
August 1987, Pediatrics,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
June 2020, Acta neurologica Belgica,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
December 2004, Biological & pharmaceutical bulletin,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
January 2007, European neurology,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
April 1991, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
November 2000, Pediatric neurology,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
November 1988, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
March 1991, Rinsho shinkeigaku = Clinical neurology,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
June 1991, The Japanese journal of psychiatry and neurology,
S Kodama, and N Sadahiro, and S Yokoyama, and M Komatsu, and H Konishi, and K Tanaka, and K Tanaka, and T Matsuo
January 2015, Pakistan journal of pharmaceutical sciences,
Copied contents to your clipboard!